Palovarotene - Clementia Pharmaceuticals

Drug Profile

Palovarotene - Clementia Pharmaceuticals

Alternative Names: Clm-001; R-667; RAR-gamma; RG-667; RO-3300074

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Clementia Pharmaceuticals; Roche
  • Class Benzoic acids; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrodysplasia ossificans progressiva
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fibrodysplasia ossificans progressiva
  • Phase II Bone disorders
  • Discontinued Emphysema

Most Recent Events

  • 01 Mar 2018 Phase-II clinical trials in Bone disorders (In infants, In children, In adolescents) in USA (unspecified route) (NCT03442985)
  • 28 Feb 2018 Clementia Pharmaceuticals plans the phase II MO-Ped trial in Bone disorders (In adolescents, In children, In infants) in Q1 2018
  • 01 Dec 2017 Clementia initiates enrolment in the phase III MOVE trial in Fibrodysplasia ossificans progressiva (In children, In adolescents, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top